Bristol Myers Squibb (CELG-RI) Cash from Operations Growth (3y) (2012 - 2026)
Bristol Myers Squibb (CELG-RI) Cash from Operations Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 27.24% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -18.38% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 13.18% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 18.04% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -0.88% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 15.19% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 39.10% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 21.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.60% |
| Mar 31, 2026 | -28.10% |
| Dec 31, 2025 | -15.79% |
| Sep 30, 2025 | 19.62% |
| Jun 30, 2025 | 20.10% |
| Mar 31, 2025 | -19.97% |
| Dec 31, 2024 | 3.04% |
| Sep 30, 2024 | 2.02% |
| Jun 30, 2024 | -8.74% |
| Mar 31, 2024 | -9.50% |
| Dec 31, 2023 | 8.22% |
| Sep 30, 2023 | 27.97% |
| Jun 30, 2023 | -25.11% |
| Mar 31, 2023 | -8.97% |
| Dec 31, 2022 | 14.87% |
| Sep 30, 2022 | 12.99% |
| Jun 30, 2022 | 2.77% |
| Mar 31, 2022 | 39.97% |
| Dec 31, 2021 | 4.50% |
| Sep 30, 2021 | 60.28% |